PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: Implications for therapy of fibrosis

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Kulkarni, Ajit A ^a   Thatcher, Thomas H ^a   Olsen, Keith C ^a   Maggirwar, Sanjay B ^a   Phipps, Richard P ^a   Sime, Patricia J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA SMOOTH MUSCLE ACTIN; BARDOXOLONE; CALPONIN; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN A1; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA; LIGAND;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG FIBROBLAST; LUNG FIBROSIS; MYOFIBROBLAST; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; DRUG EFFECT; FIBROSIS; METABOLISM; PHOSPHORYLATION;

CELL DIFFERENTIATION; FIBROSIS; HUMANS; LIGANDS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79251563128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015909     Document Type: Article

References (59)

1. Meltzer EB, Noble PW (2008) Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 3: 8.
2. Wilson MS, Wynn TA (2009) Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2: 103-121.
3. Selman M, Pardo A (2002) Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 3: 3.
4. Sime PJ, O'Reilly KM (2001) Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 99: 308-319.
5. Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, et al. (2006) More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 35: 297-325.
6. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, et al. (2005) TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 289: G116-128.
7. Guo X, Wang XF (2009) Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 19: 71-88.
8. Khalil N (1999) TGF-beta: from latent to active. Microbes Infect 1: 1255-1263.
9. Moustakas A, Heldin CH (2009) The regulation of TGFβeta signal transduction. Development 136: 3699-3714.
10. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR (2009) The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 417: 411-421.
11. Danielpour D (2005) Functions and regulation of transforming growth factorbeta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857.
12. Yamada KM, Araki M (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114: 2375-2382.
13. Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, et al. (2004) Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPKdependent induction of an autocrine growth factor. J Biol Chem 279: 1359-1367.
14. Parsons CJ, Takashima M, Rippe RA (2007) Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 22 Suppl 1: S79-84.
15. Li JD (2003) Exploitation of host epithelial signaling networks by respiratory bacterial pathogens. J Pharmacol Sci 91: 1-7.
16. Thomas PE, Peters-Golden M, White ES, Thannickal VJ, Moore BB (2007) PGE(2) inhibition of TGF-beta1-induced myofibroblast differentiation is Smadindependent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol 293: L417-428.
17. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, et al. (2007) Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 19: 761-771.
18. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA (2000) Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19: 5606-5613.
19. Parsons JT, Parsons SJ (1997) Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 9: 187-192.
20. Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, et al. (1992) Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 119: 905-912.
21. Calalb MB, Polte TR, Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15: 954-963.
22. Chen HC, Appeddu PA, Isoda H, Guan JL (1996) Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem 271: 26329-26334.
23. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, et al. (2003) Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 278: 12384-12389.
24. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 279: 33024-33034.
25. Verma A, Guha S, Wang H, Fok JY, Koul D, et al. (2008) Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 14: 1997-2005.
26. Chiu YC, Lin CY, Chen CP, Huang KC, Tong KM, et al. (2009) Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1- dependent pathway. J Immunol 183: 2785-2792.
27. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, et al. (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288: L1146-1153.
28. Ferguson HE, Thatcher TH, Olsen KC, Garcia-Bates TM, Baglole CJ, et al. (2009) Peroxisome proliferator-activated receptor-gamma ligands induce heme oxygenase-1 in lung fibroblasts by a PPARgamma-independent, glutathionedependent mechanism. Am J Physiol Lung Cell Mol Physiol 297: L912-919.
29. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
30. Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, et al. (2007) The Role of PPARs in Lung Fibrosis. PPAR Res 2007: 71323.
31. Sime PJ (2008) The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med 56: 534-538.
32. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, et al. (2008) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L891-901.
33. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, et al. (2009) Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 41: 722-730.
34. Crowder RJ, Freeman RS (1998) Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factordependent sympathetic neurons. J Neurosci 18: 2933-2943.
35. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, et al. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase. Cell 81: 727-736.
36. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, et al. (1999) Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400: 378-382.
37. Pitha-Rowe I, Liby K, Royce D, Sporn M (2009) Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest Ophthalmol Vis Sci 50: 5339-5347.
38. Straus DS, Pascual G, Li M, Welch JS, Ricote M, et al. (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97: 4844-4849.
39. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018.
40. Hart CM, Roman J, Reddy R, Sime PJ (2008) PPARgamma: a novel molecular target in lung disease. J Investig Med 56: 515-517.
41. Roman J (2008) Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med 56: 528-533.
42. Petronelli A, Pannitteri G, Testa U (2009) Triterpenoids as new promising anticancer drugs. Anticancer Drugs 20: 880-892.
43. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J (1997) Adenovectormediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100: 768-776.
44. Vinals F, Pouyssegur J (2001) Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 21: 7218-7230.
45. Kattla JJ, Carew RM, Heljic M, Godson C, Brazil DP (2008) Protein kinase B/Akt activity is involved in renal TGF-beta1-driven epithelial-mesenchymal transition in vitro and in vivo. Am J Physiol Renal Physiol 295: F215-225.
46. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, et al. (2007) Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol 84: 147-157.
47. Deeb D, Gao X, Dulchavsky SA, Gautam SC (2008) CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J Exp Ther Oncol 7: 31-39.
48. Han H, Shin SW, Seo CY, Kwon HC, Han JY, et al. (2007) 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis 12: 2101-2114.
49. Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, et al. (2009) The PPARgamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes Metab 11: 1060-1067.
50. Tan X, Dagher H, Hutton CA, Bourke JE () Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 11: 21.
51. Kim DH, Kim EH, Na HK, Sun Y, Surh YJ (2010) 15-Deoxy-Delta(12,14)- prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue. Oncogene 29: 2560-2576.
52. Kalantari P, Narayan V, Henderson AJ, Prabhu KS (2009) 15-Deoxy- Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J 23: 2366-2373.
53. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM (2007) Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma. J Biol Chem 282: 22910-22920.
54. Berra E, Diaz-Meco MT, Moscat J (1998) The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem 273: 10792-10797.
55. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, et al. (2005) Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 124: 886-892.
56. Goodwin A, Jenkins G (2009) Role of integrin-mediated TGFβeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 37: 849-854.
57. Greenberg RS, Bernstein AM, Benezra M, Gelman IH, Taliana L, et al. (2006) FAK-dependent regulation of myofibroblast differentiation. FASEB J 20: 1006-1008.
58. Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523.
59. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.